Background: Objectively measuring auditory functions has been proposed as an avenue in differentiating normal age-related cognitive dysfunction from Alzheimer's disease (AD) and its prodromal states. Previous research has suggested auditory eventrelated potentials (AERPs) to be non-invasive, cost-effective and efficient biomarkers for the diagnosis of AD. The objective of this paper is to review the published literature on AERPs measures in older adults diagnosed with AD and those at higher risk of developing AD, i.e., mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Method:The search was performed on six major electronic databases (Ovid MED-LINE, OVID EMBASE, PsycINFO, PubMed, Scopus and CINAHL Plus). Articles identified prior to 7th May 2019 were considered for this review. A random effects metaanalysis and analysis of between study heterogeneity was conducted using the Comprehensive Meta-Analysis software.
Result:The search identified 1076 articles; 74 articles met the full inclusion criteria and were included in the systematic review, and 47 articles were included into the analyses. Pooled analysis suggests that AD participants can be differentiated from controls due to significant delays in ABR, N100, P200, N200 and P300 latencies. P300 amplitude was significantly smaller in AD participants compared to controls. P300 latencies differed significantly between MCI participants and controls based on the pooled analysis.
Conclusion:The findings of this review indicate that some AERPs may be valuable biomarkers of AD. In conjunction with currently available clinical and neuropsychological assessments, AERPs can aid in screening and diagnosis of prodromal AD.